Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis

被引:72
作者
Paliwal, S
Pande, S
Kovi, RC
Sharpless, NE
Bardeesy, N
Grossman, SR
机构
[1] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA
[2] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA
[3] Univ Massachusetts, Sch Med, Gastrointestinal Canc Program, Worcester, MA 01605 USA
[4] Ctr Canc, Worcester, MA 01605 USA
[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA
[6] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA
[7] MGH Canc Ctr, Charlestown, MA 02129 USA
关键词
D O I
10.1128/MCB.26.6.2360-2372.2006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
ARF encodes a potent tumor suppressor that antagonizes MDM2, a negative regulator of p53. ARF also suppresses the proliferation of cells lacking p53, and loss of ARF in p53-null mice, compared with ARF or p53 singly null mice, results in a broadened tumor spectrum and decreased tumor latency. To investigate the mechanism of p53-independent tumor suppression by ARF, potential interacting proteins were identified by yeast two-hybrid screen. The antiapoptotic transcriptional corepressor C-terminal binding protein 2 (CtBP2) was identified, and ARF interactions with both CtBP1 and CtBP2 were confirmed in vitro and in vivo. Interaction with ARF resulted in proteasome-dependent CtBP degradation. Both ARF-induced CtBP degradation and CtBP small interfering RNA led to p53-independent apoptosis in colon cancer cells. ARF induction of apoptosis was dependent on its ability to interact with CtBP, and reversal of ARF-induced CtBP depletion by CtBP overexpression abrogated ARF-induced apoptosis. CtBP proteins represent putative targets for p53-independent tumor suppression by ARF.
引用
收藏
页码:2360 / 2372
页数:13
相关论文
共 58 条
[31]   Hdm2 recruits a hypoxia-sensitive corepressor to negatively regulate p53-dependent transcription [J].
Mirnezami, AH ;
Campbell, SJ ;
Darley, M ;
Primrose, JN ;
Johnson, PWM ;
Blaydes, JP .
CURRENT BIOLOGY, 2003, 13 (14) :1234-1239
[32]   Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis [J].
Moore, L ;
Venkatachalam, S ;
Vogel, H ;
Watt, JC ;
Wu, CL ;
Steinman, H ;
Jones, SN ;
Donehower, LA .
ONCOGENE, 2003, 22 (49) :7831-7837
[33]   FIBROBLAST GROWTH-FACTOR TREATMENT OF SWISS 3T3 CELLS ACTIVATES A SUBUNIT S6 KINASE THAT PHOSPHORYLATES A SYNTHETIC PEPTIDE SUBSTRATE [J].
PELECH, SL ;
OLWIN, BB ;
KREBS, EG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (16) :5968-5972
[34]   p19ARF directly and differentially controls the functions of c-Myc independently of p53 [J].
Qi, Y ;
Gregory, MA ;
Li, ZL ;
Brousal, JP ;
West, K ;
Hann, SR .
NATURE, 2004, 431 (7009) :712-717
[35]  
QUELLE DE, 1995, CELL, V83, P993
[36]  
Rozenblum E, 1997, CANCER RES, V57, P1731
[37]  
Sato F, 2002, CANCER RES, V62, P1148
[38]   INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53 [J].
Schmitt, CA ;
McCurrach, ME ;
de Stanchina, E ;
Wallace-Brodeur, RR ;
Lowe, SW .
GENES & DEVELOPMENT, 1999, 13 (20) :2670-2677
[39]   INK4a/ARF:: A multifunctional tumor suppressor locus [J].
Sharpless, NE .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 576 (1-2) :22-38
[40]   The differential impact of p16INK4a or p19ARF deficiency on cell growth and tumorigenesis [J].
Sharpless, NE ;
Ramsey, MR ;
Balasubramanian, P ;
Castrillon, DH ;
DePinho, RA .
ONCOGENE, 2004, 23 (02) :379-385